When Must Clinical Risks be Described in a Research Consent Document? Ron Kadden - September 10, 2008.

Slides:



Advertisements
Similar presentations
Susan Burner Bankowski, M.S., J.D. Chair, OHSU IRB
Advertisements

Chicken Soup for the Busy Coordinator September 2009.
Informed Choice. Overview Brief introduction to cases (ours, yours) Elements of informed choice Capacity Informed choice for research Return to cases.
Informed consent requirements
Exception from Informed Consent in Emergency Research Designed for implementation of research in emergency settings when exception from informed consent.
Reporting Unanticipated Problems Involving Risk to Subjects or Others and Adverse Events WFUHS Policy/Procedure Effective Date 6/1/07 Wendy Murray Monitoring.
The Journey Detectives in the Classroom - Investigation 2-6: The Journey.
天 津 医 科 大 学天 津 医 科 大 学 Clinical trail. 天 津 医 科 大 学天 津 医 科 大 学 1.Historical Background 1537: Treatment of battle wounds: 1741: Treatment of Scurvy 1948:
Treatment of Hand Ischemia Dialysis Associated Steal Syndrome (DASS) ASDIN Coding University 1.
ARISTOTLE TTR Subanalysis
Post-trial Access to Treatment by Patients participating in Clinical Trials Presented by Dr T K S Letlape Chairman: South African Medical Association President-Elect:
Capturing and Reporting Adverse Events in Clinical Research
IRB 101: Informed Consent Columbia University Medical Center IRB September 22, 2005.
Epi Team Challenge Detectives in the Classroom - Investigation 2-7: Epi Team Challenge Epi Team Challenge.
PRESENTING A PROTOCOL AN IRB INFOSHORT FEBRUARY 2013.
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
IRB – Consent Changes 5/29/14. Consent Changes Font = Calibri Clarification and addition to instructions in several sections (Header, Randomization, Voluntary.
Good Clinical Practice (GCP)- An introduction Dr Noor Ibrahim Mohamed Sakian.
Intervention Studies Principles of Epidemiology Lecture 10 Dona Schneider, PhD, MPH, FACE.
SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.
Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst.
New Adverse Event Reporting Policy Effective September 1, 2007.
Common Audit Findings UTHSC Institutional Review Board (IRB)
S1316 – The Malignant Bowel Obstruction Study Forms and Procedures Katie Arnold, MS SWOG Statistical Center Seattle, WA 10/24/2014S1316 Training1.
Planned Emergency Research Exception from Informed Consent Requirements September 2007.
Adverse Event/Unanticipated Problems Policy and Procedures November 2007.
Research Study Design. Objective- To devise a study method that will clearly answer the study question with the least amount of time, energy, cost, and.
Common Rule and FDA Regulation Comparison David Forster Jeff Cooper Gary Chadwick.
Evidence-Based Journal Article Presentation [Insert your name here] [Insert your designation here] [Insert your institutional affiliation here] Department.
The Global Health Network Marijke Geldenhuys 19 September 2014 Adhering to the GCP Principles.. what does that even mean?
Reporting Scenario # 2 September 18, Scenario # 2 Mr. Hall, 62 yr old man with acute MI, is to receive autologous mobilized PBSCs delivered via.
TARGET and TACTICS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for.
Understanding Unanticipated Problems (UPs) Elizabeth Ness, RN, MS Director, Staff Development Office of the Clinical Director Center for Cancer Research,
Introduction Clinical trials Why clinical trials? Process of a clinical trial Informed consent Patients‘ interests Rights and protection Study Registers.
Welcome New IRB Members! Today we will discuss: Your Role in the IRB: What to Know The IRB Review Process Resources Human Research Protections.
1.) *Experiment* 2.) Quasi-Experiment 3.) Correlation 4.) Naturalistic Observation 5.) Case Study 6.) Survey Research.
$100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 Terms Clinical Trial Facts.
HIPAA and Human Subjects Research IRB Member CE May 2014 Slideshow by Sean Horkheimer.
Case Studies: Puzzles in Human Research Kevin L. Nellis, M.S., M.T. (A.S.C.P.) Program Analyst, Program for Research Integrity Development and Education.
InformedConsent Q $100 Q $200 Q $300 Q $400 Q $500 Q $100 Q $200 Q $300 Q $400 Q $500 Final JeopardyJeopardy.
HUMAN TESTING: Ethical or unethical?. What is human testing? ■Human subjects research: any research or clinical investigation that involves human subjects.
Welcome New IRB Member! This brief presentation covers: Your Role in the IRB: What to Know The IRB Review Process Resources Human Research Protections.
When Do I Need Ethics Board Approval? George Schmid, M.D., M.Sc. World Health Organization/Centers for Disease Control and Prevention
HPTN Ethics Guidance for Research: Community Obligations Africa Regional Working Group Meeting, May 19-23, 2003 Lusaka, Zambia.
Risks of Standard of Care (Experimental Aspects of Study) Patrick Herbison Continuing Education for IRB Members.
10.2 Comparing Two Means Objectives SWBAT: DESCRIBE the shape, center, and spread of the sampling distribution of the difference of two sample means. DETERMINE.
GEORGIA STATE UNIVERSITY IRB ADAPTED FROM DHHS GUIDANCE ON UNANTICIPATED PROBLEMS Unanticipated Problems.
The experimental units are the households, not the individual people, since the treatments were assigned to entire households, not separately to individuals.
Main Line Hospitals Institutional Review Board Unanticipated Problems Anne Marie Hobson, BSN, JD, ORA Director Theresa Greaves, ORA Manager.
CLINICAL TRIALS.
Methods to Handle Noncompliance
IRB – Consent Changes 5/29/14
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
TOPAZ Elements The Consent Form Texas Southern University
The Clinical Trial Volunteer’s Bill of Rights
What is a Data and Safety Monitoring Plan and how do I get one?
Assign membership into BFO/OBI branches
Welcome New IRB Members!
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
PA Court Ruling on Consent
دانشیار دانشکده دندانپزشکی دانشگاه علوم پزشکی شهید صدوقی یزد
SERIOUS ADVERSE EVENTS REPORTING
Patient Autonomy & Informed consent
Clinical Studies in Orthopedics
BIOLOGY SEPTEMBER 2013 Opening Assignments.
Informed Consent (SBER)
Student TIP Therapeutic Intervention Program
A Proposed Taxonomy of Terms to Guide the Clinical Trial Recruitment Process  Neil A. Hagen, MD, FRCPC, Jackson S. Wu, MD, FRCPC, Carla R. Stiles, BN 
Common Rule Updates Tips and Tricks
Protocol Approval Criteria
Presentation transcript:

When Must Clinical Risks be Described in a Research Consent Document? Ron Kadden - September 10, 2008

The Question If a research study involves standard- of-care clinical interventions, that are being done for clinical reasons: must the risks of those clinical interventions be included in the research consent document (CD)? must the risks of those clinical interventions be included in the research consent document (CD)?

OHRP Guidance When an intervention (whether ‘standard of care’ or investigational) is dictated by a research protocol: then the reasonably foreseeable risks of that intervention are risks of the research, and must be described in the CD. then the reasonably foreseeable risks of that intervention are risks of the research, and must be described in the CD.

The Crucial Factor The research protocol must constrain the clinician’s judgment in some way: Randomization Randomization Selection of intervention Selection of intervention Timing of intervention Timing of intervention Dose/intensity of intervention Dose/intensity of intervention

The Crucial Factor If, on the other hand, the subjects will receive the intervention based entirely on clinician judgment: the risks of the intervention are NOT research risks the risks of the intervention are NOT research risks those risks should not be described in the CD those risks should not be described in the CD

Example #1 Subjects are to be randomized into 2 standard-of-care interventions: dental amalgams dental amalgams composite fillings composite fillings Since both interventions are standard- of-care, do their risks need to be described in the CD?

Example #1 YES! Since the clinician does not determine the assignment to the interventions: both standard-of-care treatments are considered research procedures both standard-of-care treatments are considered research procedures their risks must be described in the consent document their risks must be described in the consent document

Example #2 Similarly, the risks related to the use of 2 standard vascular stents, with random assignment, must be described in the CD because, here again, assignment is driven by the protocol, not by clinician judgment because, here again, assignment is driven by the protocol, not by clinician judgment

Example #2 What about other components of the intervention, such as the anesthesia associated with the standard catheterization procedures? the anesthesia associated with the standard catheterization procedures? the insertion of the catheter? the insertion of the catheter? Do their risks need to be described in the research CD???

Example #2 NO! As long as they are standard-of-care procedures, and the person was going to be getting a stent regardless of the research, those risks are not considered risks of the research and should NOT be described in the CD

Any Questions or Discussion?